Skip to main content
main-content

01.04.2015 | Case report | Ausgabe 2/2015

International Cancer Conference Journal 2/2015

Successful multimodal therapy for undifferentiated carcinoma with neuroendocrine differentiation in the clival region

Zeitschrift:
International Cancer Conference Journal > Ausgabe 2/2015
Autoren:
Kotoe Takayoshi, Shingo Tamura, Keita Uchino, Kenta Nio, Michitaka Nakano, Tsuyoshi Shirakawa, Satoshi O. Suzuki, Koji Yoshimoto, Masahiro Mizoguchi, Torahiko Nakashima, Hidetaka Yamamoto, Yoshiyuki Shioyama, Tadamasa Yoshitake, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

Abstract

Carcinomas with neuroendocrine differentiation include tumor components with characteristics of neuroendocrine tumors of carcinomas of the lung, gastrointestinal tract, prostate, and breast. No clear definition or treatment has been established. A 66-year-old female was admitted to our hospital for a sore throat and otalgia. Magnetic resonance imaging showed a locally invasive tumor with a diameter of 45 mm in the clival region. Histopathological examination revealed that the tumor consisted of densely packed undifferentiated tumor cells with high mitotic activity. Two cellular components were present: one proliferating in solid nests that were immunopositive for cytokeratin, and the other that was diffusely proliferating and immunopositive for neuroendocrine markers. The tumor was thus diagnosed as undifferentiated carcinoma with neuroendocrine differentiation. The patient was treated with four cycles of cisplatin and etoposide and a total of 70 Gy radiotherapy. A complete response was achieved and maintained without therapy for 16 months. Metastasis to the lymph nodes, liver, and bone then appeared, and a lymphadenectomy revealed undifferentiated carcinoma without neuroendocrine differentiation. The patient died because of the tumor 36 months after the initial diagnosis. Because undifferentiated carcinomas with neuroendocrine differentiation in the skull are exceedingly rare, we report this case in which the tumor was controlled with chemoradiotherapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2015

International Cancer Conference Journal 2/2015 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise